Found 31 clinical trials
-
Multi-country trial
-
Phase 1 trial
-
Accepting Seniors
-
Accepting adults
-
100s of participants
-
An interventional trial
-
For all genders
-
Currently Recruiting
Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651)
The purpose of this study is to determine safety and tolerability and to establish a preliminary recommended Phase 2 dose (RP2D) for the following combinations: pembrolizumab plus binimetinib
- 60 views
- 25 Jan, 2021
- 14 locations
-
Phase 1 trial
-
Accepting Seniors
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For all genders
-
Currently Recruiting
A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers
The goal of this trial is to test the safety and efficacy of an innovative combination aimed to more profoundly inhibit ERK signaling in tumors.
- 0 views
- 26 Jan, 2021
- 6 locations
-
Phase 2 trial
-
Accepting Seniors
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For all genders
-
Currently Recruiting
Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant
who do not have this mutation, BRAF inhibitors are not a treatment option. We found that in hairy cell leukemia, when BRAF is not mutated, the MEK gene frequently is. Binimetinib is a MEK inhibitor
- 0 views
- 18 Jan, 2021
- 1 location
-
Phase 2 trial
-
Accepting Seniors
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For all genders
-
Currently Recruiting
Encorafenib Plus Binimetinib for People With BRAF V600E Mutated Relapsed/Refractory HCL
with a combination of encorafenib and binimetinib in BRAF mutant HCL is more effective than treatment with vemurafenib. Eligibility People ages 18 and older
- 0 views
- 17 Jan, 2021
- 1 location
-
Unknown Phase
-
Accepting Seniors
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For all genders
-
Currently Recruiting
MEK and Autophagy Inhibition in Metastatic/Locally Advanced Unresectable Neuroblastoma RAS (NRAS) Melanoma
approved in NRAS mutated melanoma as a second line treatment, because although the use of a MEK inhibitor (binimetinib) alone was superior to the gold standard chemotherapy (dacarbazine) in a phase 3 trial
- 0 views
- 25 Jan, 2021
- 5 locations
-
Multi-country trial
-
Phase 2 trial
-
Accepting Seniors
-
Accepting adults
-
100s of participants
-
An interventional trial
-
For all genders
-
Currently Recruiting
Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib
12 weeks with encorafenib + binimetinib followed by combination immunotherapy with nivolumab + ipilimumab improves progression free survival compared to combination immunotherapy nivolumab
- 11 views
- 24 Jan, 2021
- 51 locations
-
Multi-country trial
-
Phase 2 trial
-
Accepting Seniors
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For all genders
-
Pulmonary/Respiratory Diseases
-
Currently Recruiting
An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600E-mutant Non-small Cell Lung Cancer
This is an open-label, multicenter, non-randomized, Phase 2 study to determine the safety, tolerability and efficacy of encorafenib given in combination with binimetinib in patients with
- 3 views
- 26 Jan, 2021
- 213 locations
-
Multi-country trial
-
Phase 1 trial
-
Accepting pediatric ages
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For all genders
-
Dermatology
-
Currently Recruiting
Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma
This is a multicenter Phase 1b, open-label study to evaluate the pharmacokinetic, safety and efficacy of binimetinib and encorafenib co-administered to adolescent patients with BRAF V600-mutant
- 16 views
- 17 Jan, 2021
- 20 locations
-
Multi-country trial
-
Phase 1 trial
-
Accepting Seniors
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For all genders
-
Currently Recruiting
Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors
This is an open-label, 3-arm, fixed-sequence study to evaluate the effect of single and multiple oral doses of encorafenib in combination with binimetinib on the single oral dose
- 14 views
- 15 Jan, 2021
- 77 locations
-
Multi-country trial
-
Phase 2 trial
-
Accepting Seniors
-
Accepting adults
-
100s of participants
-
An interventional trial
-
For all genders
-
Currently Recruiting
An Open-Label Randomized Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-mutant Melanoma Brain Metastasis
This is a multicenter, randomized open-label Phase 2 study to assess the safety, efficacy and pharmacokinetic (PK) of 2 dosing regimens of encorafenib + binimetinib combination in patients with
- 44 views
- 19 Nov, 2020
- 219 locations